{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T06:04:15Z","timestamp":1780639455462,"version":"3.54.1"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014418","name":"Harbin Medical University Cancer Hospital","doi-asserted-by":"publisher","award":["JJQN2023-09"],"award-info":[{"award-number":["JJQN2023-09"]}],"id":[{"id":"10.13039\/100014418","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study evaluated the cost-effectiveness of Atezolizumab plus Bevacizumab versus Rivoceranib plus Camrelizumab as first-line treatment of unresectable hepatocellular carcinoma (HCC) from the perspective of healthcare payers in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An economic evaluation using a 3-state partitioned survival model assessed the cost-effectiveness of Atezolizumab plus Bevacizumab versus Rivoceranib plus Camrelizumab. The Kaplan\u2013Meier curves for overall survival (OS) and progression-free survival (PFS) from two clinical trials were digitally extracted, and the Weibull models were applied at the end of the trials to extrapolate long-term survival. The cost and health utility data were sourced from the published literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The anticipated cost for Atezolizumab plus Bevacizumab exceeded that for Rivoceranib plus Camrelizumab (109,555.94 USD vs. 15,264.92 USD). The estimated utility for Atezolizumab plus Bevacizumab was decreased compared to that of Rivoceranib plus Camrelizumab (1.47 QALYs vs. 1.59 QALYs). The ICER was \u2212742,858.34 USD\/QALY, suggesting the Rivoceranib plus Camrelizumab treatment was cost-effective compared to Atezolizumab plus Bevacizumab as the first-line treatment for advanced or metastatic HCC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Rivoceranib plus Camrelizumab was cost-effective compared to Atezolizumab plus Bevacizumab as a first-line treatment for advanced or metastatic HCC patients in China.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1749414","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:37:13Z","timestamp":1780637833000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness analysis of Atezolizumab plus bevacizumab vs. Rivoceranib plus Camrelizumab as first-line treatment for unresectable hepatocellular carcinoma"],"prefix":"10.3389","volume":"14","author":[{"given":"Mengmeng","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Harbin Medical University Cancer Hospital","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Harbin Medical University Cancer Hospital","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e214708","DOI":"10.1001\/jamanetworkopen.2021.4708","article-title":"Estimated projection of US Cancer incidence and death to 2040","volume":"4","author":"Rahib","year":"2021","journal-title":"JAMA Netw Open"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.cgh.2019.04.043","article-title":"Hepatocellular carcinoma incidence is decreasing among younger adults in the United States","volume":"18","author":"Rich","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.soc.2023.06.004","article-title":"Changing epidemiology of hepatocellular carcinoma within the United States and worldwide","volume":"33","author":"Rich","year":"2024","journal-title":"Surg Oncol Clin N Am"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S0140-6736(19)30427-1","article-title":"Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the global burden of disease study 2017","volume":"394","author":"Zhou","year":"2019","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3350\/cmh.2022.0402","article-title":"Clinical practice guidelines and real-life practice in hepatocellular carcinoma: a Chinese perspective","volume":"29","author":"Xie","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"ref8","year":"2025"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000546574","article-title":"China liver Cancer guidelines for the diagnosis and treatment of hepatocellular carcinoma (2024 edition)","volume":"14","author":"Zhou","year":"2025","journal-title":"Liver Cancer"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.semcancer.2017.12.002","article-title":"Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics","volume":"52","author":"Hegde","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"12624","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat Commun"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s10120-023-01455-5","article-title":"Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial","volume":"27","author":"Kang","year":"2024","journal-title":"Gastric Cancer"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of Camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","journal-title":"JAMA"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1158\/1078-0432.CCR-18-2484","article-title":"Anti-PD-1 antibody SHR-1210 combined with Apatinib for advanced hepatocellular carcinoma, gastric, or Esophagogastric junction Cancer: an open-label, dose escalation and expansion study","volume":"25","author":"Xu","year":"2019","journal-title":"Clin Cancer Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","article-title":"Network meta-analysis: an introduction for clinicians","volume":"12","author":"Rouse","year":"2017","journal-title":"Intern Emerg Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2529573","DOI":"10.1080\/07853890.2025.2529573","article-title":"Cost-effectiveness analysis of capecitabine versus active monitoring in stable or responding metastatic colorectal cancer after 16 weeks of first-line therapy","volume":"57","author":"Liu","year":"2025","journal-title":"Ann Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s41669-023-00414-1","article-title":"A simple cost-effectiveness model of screening: an open-source teaching and research tool coded in R","volume":"7","author":"Lin","year":"2023","journal-title":"Pharmacoecon Open"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1080\/14737167.2025.2521439","article-title":"Cost-effectiveness analysis of adagrasib with or without cetuximab in the treatment of colorectal cancer patients with mutated KRAS G12C","volume":"25","author":"Yao","year":"2025","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1120009X.2025.2524906","article-title":"Cost-effectiveness analysis of dostarlimab plus chemotherapy versus pembrolizumab plus chemotherapy as first-line treatment of metastatic non-squamous non-small cell lung cancer","volume":"28","author":"Liu","year":"2025","journal-title":"J Chemother"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1080\/14737167.2025.2509706","article-title":"Cost-effectiveness analysis of FOLFOXIRI plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment of metastatic colorectal cancer","volume":"25","author":"Liu","year":"2025","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1080\/14737167.2025.2521444","article-title":"Cost-effectiveness analysis of sotorasib plus panitumumab in the treatment of refractory colorectal cancer with mutated KRAS G12C in the USA","volume":"25","author":"Liu","year":"2025","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/14737167.2025.2603943","article-title":"Cost-effectiveness analysis of larotrectinib vs standard of care for treatment of metastatic NTRK fusion colorectal cancer","volume":"26","author":"Zhong","year":"2026","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/14737167.2021.1893167","article-title":"Will the Markov model and partitioned survival model lead to different results? A review of recent economic evidence of cancer treatments","volume":"21","author":"Rui","year":"2021","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e449","DOI":"10.1016\/j.clgc.2023.05.009","article-title":"Cost-effectiveness of Nivolumab plus Cabozantinib versus Cabozantinib as first-line treatment of metastatic renal cell carcinoma","volume":"21","author":"Liu","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"ref31","author":"Yao","year":"2025"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e094804","DOI":"10.1136\/bmjopen-2024-094804","article-title":"Cost-effectiveness of atezolizumab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in the US and Chinese setting: a modelling comparison study","volume":"15","author":"Liu","year":"2025","journal-title":"BMJ Open"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/bcp.16367","article-title":"Cost-effectiveness of first-line systemic therapies for unresectable hepatocellular carcinoma","volume":"18","author":"Lian","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s11096-024-01721-1","article-title":"Cost-effectiveness analysis of fruquintinib in Chinese patients with refractory metastatic colorectal cancer","volume":"46","author":"Huang","year":"2024","journal-title":"Int J Clin Pharm"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1049947","DOI":"10.3389\/fpubh.2023.1049947","article-title":"Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04","volume":"11","author":"Zhan","year":"2023","journal-title":"Front Public Health"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/ejhpharm-2020-002208","article-title":"Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non-small-cell lung cancer in China","volume":"29","author":"Jiang","year":"2022","journal-title":"Eur J Hosp Pharm"},{"key":"ref37","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"1997"},{"key":"ref38","volume-title":"China Guidelines for Pharmacoeconomic Evaluations (2020 Version)","author":"Liu","year":"2020"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/13696998.2022.2043634","article-title":"Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H\/dMMR colorectal cancer in the United States","volume":"25","author":"Aguiar-Ib\u00e1\u00f1ez","year":"2022","journal-title":"J Med Econ"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e062832","DOI":"10.1136\/bmjopen-2022-062832","article-title":"Cost-effectiveness and willing-to-pay thresholds for vertebral augmentation of osteoporotic vertebral fractures, what are they based on: a systematic review","volume":"13","author":"Pron","year":"2023","journal-title":"BMJ Open"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e218787","DOI":"10.1001\/jamanetworkopen.2021.8787","article-title":"Cost-effectiveness of Nivolumab-Ipilimumab combination therapy for the treatment of advanced non-small cell lung cancer","volume":"4","author":"Courtney","year":"2021","journal-title":"JAMA Netw Open"},{"key":"ref42","first-page":"60","article-title":"Application of partition survival model in pharmacoeconomic evaluation","volume":"38","author":"Shao","year":"2019","journal-title":"China Health Econ"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1080\/1120009X.2022.2162220","article-title":"Cost-effectiveness analysis of pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer","volume":"35","author":"Liu","year":"2023","journal-title":"J Chemother"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e210037","DOI":"10.1001\/jamanetworkopen.2021.0037","article-title":"Cost-effectiveness of Atezolizumab plus bevacizumab vs Sorafenib as first-line treatment of Unresectable hepatocellular carcinoma","volume":"4","author":"Su","year":"2021","journal-title":"JAMA Netw Open"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1749414\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:37:15Z","timestamp":1780637835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1749414\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":44,"alternative-id":["10.3389\/fpubh.2026.1749414"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1749414","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"article-number":"1749414"}}